Biogen, Inc.
Records under this name other than the patents Biogen, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,635,466 | DNA sequences, recombinant DNA molecules and processes for producing human fibroblast interferon-like polypeptides Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,198,955 | Method for Reducing Flu-Like Symptoms Associated with Intramuscular Administration of Interferon Using a Fast Titration Escalating Dosing Regimen Formerly held In force · High confidence | In force | High confidence | |
| US 10,500,254 | Method for Reducing Flu-Like Symptoms Associated with Intramuscular Administration of Interferon Using a Fast Titration Escalating Dosing Regimen Formerly held In force · High confidence | In force | High confidence | |
| US 10,450,379 | Method for Treating Joint Damage Term ended Term ended Nov 14, 2026 · High confidence | Term ended | Term ended Nov 14, 2026 | High confidence |
| US 10,654,940 | Method for Treating Joint Damage Term ended Term ended Nov 14, 2026 · High confidence | Term ended | Term ended Nov 14, 2026 | High confidence |
| US 7,588,755 | DNA sequences, recombinant DNA molecules and processes for producing human fibroblast interferon-like polypeptides Formerly held In force Term ended Sep 15, 2026 · From the USPTO record | In force | Term ended Sep 15, 2026 | From the USPTO record |
| US 7,759,117 | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures Term ended Term ended Feb 6, 2026 · From the USPTO record | Term ended | Term ended Feb 6, 2026 | From the USPTO record |
| US 11,192,856 | Process for preparing alpha-carboxamide pyrrolidine derivatives Lapsed on the fee record Ended Dec 7, 2025 · From the USPTO record | Lapsed on the fee record | Ended Dec 7, 2025 | From the USPTO record |
| US 11,149,039 | Process for preparing spiro derivatives Lapsed on the fee record Ended Oct 19, 2025 · From the USPTO record | Lapsed on the fee record | Ended Oct 19, 2025 | From the USPTO record |
| US 9,545,086 | BAFF, Inhibitors Thereof and Their Use in the Modulation of B-Cell Response and Treatment of Autoimmune Disorders Formerly held Term ended Term ended Jun 28, 2025 · Medium confidence | Term ended | Term ended Jun 28, 2025 | Medium confidence |